Navigation Links
Profil Institute Appoints Dan Bradbury, former Amylin Pharmaceutical CEO, to Board of Directors
Date:11/4/2013

SAN DIEGO, Nov. 4, 2013 /PRNewswire/ -- Profil® Institute for Clinical Research, Inc., a company providing science-driven early phase diabetes and obesity clinical research, announced today the appointment of Dan Bradbury, Managing Member of BioBrit, LLC and former Amylin Pharmaceutical CEO, to its Board of Directors.  Mr. Bradbury joins Profil Institute's current Board Directors Dr. John Amatruda, a pharmaceutical research executive and former Senior Vice President and Head of Diabetes and Obesity at Merck Research Laboratories; Dr. Jerrold Olefsky, Professor of Medicine at the University of California, San Diego (UCSD) Division of Endocrinology and Metabolism and the Associate Dean of Scientific Affairs for the UCSD School of Medicine; Dr. Linda Morrow, Profil Institute's COO; and Dr. Marcus Hompesch, Profil Institute's President and CEO.

"Dan Bradbury is a highly regarded and prominent leader in the global pharmaceutical industry. We are pleased to have a person of his business acumen and relevant experience join our Board of Directors," said Dr. Hompesch. "With Mr. Bradbury's considerable experience in driving strategic growth, I am certain that he will bring tremendous insight and guidance to help further shape the company's strategic course."

"Profil Institute inhabits a unique space in today's clinical research industry as a therapeutically focused CRO capable of providing competent and robust guidance on all aspects of early clinical development strategy and execution, and as an innovator of new methodologies to generate more meaningful data for early phase studies," said Mr. Bradbury.  "Profil Institute is a growth story that I'm excited to be a part of and am pleased to join at this time of strategic decisions for the continued expansion for the company."

Mr. Bradbury is a life sciences executive with over 30 years of experience creating and implementing strategies that transform businesses and bring novel medicines to market.  He is currently Managing Member of BioBrit, LLC, a life sciences consulting and investment firm.  Prior to that, Mr. Bradbury served as Amylin Pharmaceuticals' President, Chief Executive Officer and Director from 2007 until its acquisition by Bristol-Myers Squibb Company in 2012. Amylin is a biopharmaceutical company focused on metabolic diseases and based in San Diego. During Mr. Bradbury's 18-year tenure at Amylin, the company launched three first-in-class medicines, including the first once-a-week therapy to treat diabetes and was listed on the Nasdaq 100.  Prior to joining Amylin, Mr. Bradbury worked in marketing and sales roles for ten years at SmithKline Beecham Pharmaceuticals. 

Mr. Bradbury serves on the Board of Directors of Corcept Therapeutics, Geron Corporation, Illumina, Inc., BioMed Realty, Biocon Limited, Castle Biosciences, Inc. (Private), DiaVacs (Private) and Microdermis, Inc. (Private). He also serves on the Board of Trustees of the Keck Graduate Institute, the Investor Growth Capital Advisory Board, and the BioMed Ventures Advisory Committee. In addition to his Board positions, Mr. Bradbury serves on the University of California San Diego's Rady School of Management's Advisory Council and the University of Miami's Innovation Corporate Advisory Council.

About Profil® Institute for Clinical Research, Inc.
Profil Institute is a Center of Excellence performing early phase clinical research of drugs and devices for diabetes and obesity and providing scientific support for metabolic drug target profiling, clinical development planning, publication activities and the establishment of scientific advisory boards. The company's scientific expertise, metabolic clinical research methodologies, and automated glucose clamp technology enable Profil Institute to execute highly complex studies and have led Profil Institute to be a highly regarded clinical research institute for early phase metabolic drug studies. Profil Institute has been involved with every clinically relevant drug class in diabetes and in more than 200 clinical studies since the company's inception in 2004. For more information, visit www.profilinstitute.com


'/>"/>
SOURCE Profil Institute for Clinical Research
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. A boost for cellular profiling
2. AKESOgen and Identitas partner to provide a comprehensive Next Generation Forensic profiling solution
3. Gastric bypass surgery alters gut microbiota profile along the intestine
4. NIH awards Scripps Translational Science Institute $29 million grant
5. MARC travel awards announced for 2013 Institute on Teaching and Mentoring
6. Ludwig scientist Richard D. Kolodner elected to the Institute of Medicine
7. Leader of smoking cessation and tobacco prevention efforts receives Institute of Medicines 2013 Lienhard Award
8. Institute of Medicine Elects 70 New Members, 10 Foreign Associates
9. Carnegie Mellon President Subra Suresh elected to Institute of Medicine
10. Institute of Medicine honors members for outstanding service
11. Wyss Institute core faculty member elected to the Institute of Medicine of the National Academies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2019)... ... September 20, 2019 , ... A new ... client demands for precision medicine products. The report, Lab Instrumentation Markets for ... 2018, the pharma/bio sector is the largest source of demand for laboratory instrumentation. ...
(Date:9/17/2019)... ... 17, 2019 , ... Dual-board certified periodontist and implant surgeon, ... of Implant Dentistry (ASID) Accreditation Courses. His lecture, “Understanding the Soft and Hard ... Modern Implant Dentistry course. Dr. Kim’s expertise comes from years of experience providing ...
(Date:9/11/2019)... ... ... Greenberg Traurig, LLP attorneys Stephen Baird , - Marcella C. ... 9-10, at the Hyatt Regency, Minneapolis. Greenberg Traurig is a founding sponsor of DeviceTalks, ... have been featured speakers at every DeviceTalks conference since 2011. , On Sept. 9, ...
Breaking Biology News(10 mins):
(Date:9/17/2019)... ... 17, 2019 , ... Geneticure, Inc., a Rochester Minnesota company ... the U.S. Patent and Trademark Office (USPTO) and European Patent Office (EPO) have ... for hypertension treatment. , The patent applies to Geneticure’s first pharmacogenomics test, ...
(Date:9/17/2019)... ... September 16, 2019 , ... When a lot of ... that allow for the complete 3D characterization of tissues through the use of confocal ... an imaging, image analysis and advanced cell culture focused contract research organization and today ...
(Date:9/17/2019)... ... 16, 2019 , ... MyBioGate Global Healthcare Innovation Competition Boston ... Boston, a forum organized by MyBioGate, Inc. and CUBIO Innovation Center that promotes ... process of evaluation, twelve companies out of over 200 applications were selected to ...
(Date:9/11/2019)... , ... September 09, 2019 , ... ... (IRT) for clinical trial randomization and drug supply chain management, today announced its ... the global life sciences industry. , “The integration between Veeva Vault EDC and ...
Breaking Biology Technology: